MAIA Biotechnology (MAIA) Share-based Compensation (2021 - 2026)
MAIA Biotechnology (MAIA) posted quarterly Share-based Compensation of $3.1 million for Q1 2026, up 736.1% year-over-year from $371472.0 in Q1 2025, and up 283.07% quarter-over-quarter from $810796.0 in Q4 2025.
MAIA Biotechnology (MAIA) Share-based Compensation (2021 - 2026) Analysis & Trends
MAIA Biotechnology (MAIA) has reported Share-based Compensation for 6 consecutive years, with $3.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Share-based Compensation rose 736.1% year-over-year to $3.1 million; the TTM figure through Mar 2026 stood at $3.1 million (up 60.57% YoY), while the FY2025 annual figure was $3.5 million, up 31.47% from the prior year.
- Share-based Compensation climbed to $3.1 million in Q1 2026 per MAIA's latest filing, from $810796.0 in the prior quarter.
- Across five years, Share-based Compensation topped out at $3.9 million in Q3 2025 and bottomed at $349965.0 in Q1 2024.
- Historically, Share-based Compensation has averaged $960863.2 across 5 years, with a median of $584768.0 in 2022.
- Annual changes were most pronounced in 2024 — Share-based Compensation sank 49.08% — and 2025, when it jumped 761.37%.
- MAIA Biotechnology's Share-based Compensation stood at $488891.0 in 2022, then jumped by 178.58% to $1.4 million in 2023, then sank by 49.08% to $693443.0 in 2024, then increased by 16.92% to $810796.0 in 2025, then soared by 283.07% to $3.1 million in 2026.
- Business Quant data shows MAIA's Share-based Compensation at $3.1 million in Q1 2026, $810796.0 in Q4 2025, and $3.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 86.63 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 28.05 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 41.25 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | MAIA Biotechnology | 84.50 Mn | 56.91 Mn | - | 5.89 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.89 Mn |
| Jun 30, 2026 | 5.89 Mn |
| Mar 31, 2026 | 3.11 Mn |
| Mar 31, 2026 | 3.11 Mn |
| Dec 31, 2025 | 810,796.00 |
| Dec 31, 2025 | 810,796.00 |
| Sep 30, 2025 | 3.92 Mn |
| Sep 30, 2025 | 3.92 Mn |
| Jun 30, 2025 | 802,484.00 |
| Jun 30, 2025 | 802,484.00 |
| Mar 31, 2025 | 371,472.00 |
| Mar 31, 2025 | 371,472.00 |
| Dec 31, 2024 | 693,443.00 |
| Dec 31, 2024 | 693,443.00 |
| Sep 30, 2024 | 455,388.00 |
| Sep 30, 2024 | 455,388.00 |
| Jun 30, 2024 | 413,948.00 |
| Jun 30, 2024 | 413,948.00 |
| Mar 31, 2024 | 349,965.00 |
| Mar 31, 2024 | 349,965.00 |